Brokerages Set BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) PT at $330.89

Key Points

• BeOne Medicines Ltd. has received an average recommendation of "Buy" from seven analysts, with an average 12-month price target of approximately $330.89.
• Recent insider activity includes Lai Wang selling 259 shares for around $79,000, and COO Xiaobin Wu selling nearly 40,000 shares valued at over $12.1 million.
• For the most recent quarter, BeOne Medicines reported $1.32 billion in revenue and an earnings per share of $0.84, exceeding analyst expectations.

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) has earned a consensus recommendation of "Buy" from the seven ratings firms that are presently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $330.8889.

ONC has been the topic of several research reports. Guggenheim lifted their target price on BeOne Medicines from $350.00 to $365.00 and gave the stock a "buy" rating in a report on Thursday, August 7th. Morgan Stanley lifted their price objective on BeOne Medicines from $313.00 to $330.00 and gave the stock an "overweight" rating in a research note on Friday, June 27th. Wall Street Zen raised BeOne Medicines from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. Royal Bank Of Canada increased their target price on BeOne Medicines from $349.00 to $364.00 and gave the company an "outperform" rating in a research report on Thursday, August 7th. Finally, JPMorgan Chase & Co. raised their target price on shares of BeOne Medicines from $321.00 to $345.00 and gave the company an "overweight" rating in a report on Thursday, July 17th.

BeOne Medicines Price Performance

Shares of NASDAQ:ONC traded up $8.09 during midday trading on Wednesday, reaching $306.05. 360,221 shares of the company were exchanged, compared to its average volume of 328,635. The stock has a market cap of $33.54 billion, a PE ratio of -176.91 and a beta of 0.21. The business's fifty day moving average is $285.26 and its two-hundred day moving average is $260.54. BeOne Medicines has a one year low of $170.99 and a one year high of $330.63. The company has a current ratio of 1.95, a quick ratio of 1.72 and a debt-to-equity ratio of 0.04.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.84 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.36. BeOne Medicines had a negative net margin of 3.89% and a negative return on equity of 1.22%. The company had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.24 billion. As a group, analysts predict that BeOne Medicines will post -5.82 earnings per share for the current year.

Insider Transactions at BeOne Medicines

In other news, insider Lai Wang sold 259 shares of BeOne Medicines stock in a transaction that occurred on Wednesday, July 30th. The stock was sold at an average price of $305.00, for a total value of $78,995.00. Following the completion of the transaction, the insider owned 1,023,529 shares in the company, valued at approximately $312,176,345. The trade was a 0.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Aaron Rosenberg sold 1,190 shares of the business's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $290.47, for a total value of $345,659.30. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 203,730 shares of company stock worth $57,617,229. 6.62% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On BeOne Medicines

Several hedge funds and other institutional investors have recently made changes to their positions in ONC. Anchor Investment Management LLC purchased a new position in shares of BeOne Medicines during the 2nd quarter worth about $26,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of BeOne Medicines in the second quarter worth approximately $28,000. Daiwa Securities Group Inc. bought a new stake in shares of BeOne Medicines during the 2nd quarter worth approximately $35,000. Farther Finance Advisors LLC bought a new stake in shares of BeOne Medicines during the 2nd quarter worth approximately $39,000. Finally, Signaturefd LLC purchased a new position in BeOne Medicines during the 2nd quarter valued at $49,000. Hedge funds and other institutional investors own 48.55% of the company's stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.